(JDOC) JPMorgan Healthcare Leaders - Ratings and Ratios
Exchange: NASDAQ •
Country: USA •
Currency: USD •
Type: Etf •
ISIN: US46654Q7658
Pharmaceutical, Biotechnology, Healthcare Services, Medical Technology, Life Sciences
Description: JDOC JPMorgan Healthcare Leaders
The fund will invest primarily in equity securities issued by pharmaceutical, biotechnology, healthcare services, healthcare technology, medical technology and life sciences companies which the adviser believes are leaders and where the magnitude and/or duration of future growth for these companies is underappreciated by the market. Under normal circumstances, the fund invests at least 80% of its assets in the equity securities of healthcare companies.
JDOC ETF Overview
| Market Cap in USD | 8m |
| Category | Health |
| TER | 0.65% |
| IPO / Inception | 2023-11-01 |
JDOC ETF Ratings
| Growth Rating | -16.3% |
| Fundamental | - |
| Dividend Rating | 55.5% |
| Return 12m vs S&P 500 | -26.4% |
| Analyst Rating | - |
JDOC Dividends
| Dividend Yield 12m | 5.42% |
| Yield on Cost 5y | 6.10% |
| Annual Growth 5y | 493.40% |
| Payout Consistency | 66.7% |
| Payout Ratio | % |
JDOC Growth Ratios
| Growth Correlation 3m | 35.6% |
| Growth Correlation 12m | -79.1% |
| Growth Correlation 5y | -21.1% |
| CAGR 5y | 6.73% |
| CAGR/Max DD 5y | 0.32 |
| CAGR/Mean DD 5y | 1.26 |
| Sharpe Ratio 12m | 0.20 |
| Alpha | -29.25 |
| Beta | 0.884 |
| Volatility | 12.09% |
| Current Volume | 0.2k |
| Average Volume 20d | 0.1k |
| Stop Loss | 50.4 (-3.1%) |
| Signal | -0.57 |
What is the price of JDOC shares?
As of September 09, 2025, the stock is trading at USD 52.02 with a total of 178 shares traded.
Over the past week, the price has changed by +0.83%, over one month by +6.53%, over three months by +3.92% and over the past year by -11.50%.
Over the past week, the price has changed by +0.83%, over one month by +6.53%, over three months by +3.92% and over the past year by -11.50%.
Is JPMorgan Healthcare Leaders a good stock to buy?
Neither. Based on ValueRay´s Analyses, JPMorgan Healthcare Leaders is currently (September 2025)
neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of -16.33 and therefor a technical neutral rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of JDOC is around 60.19 USD . This means that JDOC is currently undervalued and has a potential upside of +15.71% (Margin of Safety).
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of JDOC is around 60.19 USD . This means that JDOC is currently undervalued and has a potential upside of +15.71% (Margin of Safety).
Is JDOC a buy, sell or hold?
JPMorgan Healthcare Leaders has no consensus analysts rating.
What are the forecasts/targets for the JDOC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 67.6 | 29.9% |
Last update: 2025-08-30 04:46
JDOC Fundamental Data Overview
Market Cap USD = 7.73m (7.73m USD * 1.0 USD.USD)
CCE Cash And Equivalents = unknown
Revenue TTM is 0, using Net Income TTM 0.0 + Cost of Revenue 0.0 = 0.0 USD
Beta = 0.0
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 7.73m USD (7.73m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = none (FCF TTM 0.0 / Enterprise Value 7.73m)
FCF Margin = unknown (Revenue TTM is 0)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 7.73m / Book Value Of Equity 0.0)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default)
NOPAT = 0.0 (EBIT 0.0, no tax applied on loss)
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown Debt (none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = none (Debt none / FCF TTM 0.0)
Total Stockholder Equity = unknown
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity none)
RoCE = unknown (Ebit 0.0 / (Equity none + L.T.Debt none))
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, Ebit 0.0)
WACC = unknown (E(7.73m)/V(0.0) * Re(9.27%)) + (D(none)/V(0.0) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.27% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
CCE Cash And Equivalents = unknown
Revenue TTM is 0, using Net Income TTM 0.0 + Cost of Revenue 0.0 = 0.0 USD
Beta = 0.0
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 7.73m USD (7.73m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = none (FCF TTM 0.0 / Enterprise Value 7.73m)
FCF Margin = unknown (Revenue TTM is 0)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 7.73m / Book Value Of Equity 0.0)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default)
NOPAT = 0.0 (EBIT 0.0, no tax applied on loss)
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown Debt (none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = none (Debt none / FCF TTM 0.0)
Total Stockholder Equity = unknown
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity none)
RoCE = unknown (Ebit 0.0 / (Equity none + L.T.Debt none))
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, Ebit 0.0)
WACC = unknown (E(7.73m)/V(0.0) * Re(9.27%)) + (D(none)/V(0.0) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.27% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for JDOC ETF
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle